Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo B Gambacorti-Passerini

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|February 8, 2003
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemiasCarlo B Gambacorti-Passerini, Rosalind H Gunby, Rocco Piazza, et al.
Cancer Research|September 9, 2010
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2Luca Mologni, Hafedh Dekhil, Monica Ceccon, et al.
Blood Cells, Molecules & Diseases|October 9, 2002
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patientsCarlo B Gambacorti-Passerini, Francesca Rossi, Magda Verga, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Blood|May 3, 2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers, Andreas Hochhaus, Eric Feldman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|February 8, 2003
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemiasCarlo B Gambacorti-Passerini, Rosalind H Gunby, Rocco Piazza, et al.
Cancer Research|September 9, 2010
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2Luca Mologni, Hafedh Dekhil, Monica Ceccon, et al.
Blood Cells, Molecules & Diseases|October 9, 2002
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patientsCarlo B Gambacorti-Passerini, Francesca Rossi, Magda Verga, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Blood|May 3, 2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers, Andreas Hochhaus, Eric Feldman, et al.
Pageof 1